Skip to main content
Premium Trial:

Request an Annual Quote

Luminex Q2 Revenues Climb 16 Percent, Loss Narrows

NEW YORK, July 28 (GenomeWeb News) - Luminex yesterday reported increased revenues and a narrowing loss for the second quarter of 2005.


Revenues for the quarter totaled $10.7 million, a 16 percent increase over last year's revenues of $9.2 million during the same quarter. Of total revenues, $4.4 million came from sales of Luminex instruments, $3.9 million from consumables, $1.2 million from royalties, and $1.1 million from other sources.


Research and development costs climbed to $1.5 million, up from $1 million during the year-ago quarter.


Luminex's net loss declined to $363,000, or $.01 per share, from $1.1 million, or $.04 per share, for last year's second quarter.


As of June 30, Luminex had $19.5 million in cash and cash equivalents, and $8.9 million in short-term investments.

The Scan

Self-Reported Hearing Loss in Older Adults Begins Very Early in Life, Study Says

A JAMA Otolaryngology — Head & Neck Surgery study says polygenic risk scores associated with hearing loss in older adults is also associated with hearing decline in younger groups.

Genome-Wide Analysis Sheds Light on Genetics of ADHD

A genome-wide association study meta-analysis of attention-deficit hyperactivity disorder appearing in Nature Genetics links 76 genes to risk of having the disorder.

MicroRNA Cotargeting Linked to Lupus

A mouse-based study appearing in BMC Biology implicates two microRNAs with overlapping target sites in lupus.

Enzyme Involved in Lipid Metabolism Linked to Mutational Signatures

In Nature Genetics, a Wellcome Sanger Institute-led team found that APOBEC1 may contribute to the development of the SBS2 and SBS13 mutational signatures in the small intestine.